Investigators at St. John’s University have published preclinical data regarding their endothelin-1 receptor (ETRA) antagonist HJP-272 for the potential treatment of cancer.

The updated recommendations now include TRYVIO™ (aprocitentan) – the first and only hypertension treatment targeting the ...

Background—Endothelin-1 (ET-1) is a potent positive inotrope in vitro, but its physiological effects on intrinsic myocardial contractile function in humans in vivo are unknown. Plasma ET-1 levels are ...

Background—In humans, endothelin (ET)-1 could be implicated in the pathophysiology of several cardiovascular diseases, including essential hypertension. We therefore evaluated the role of ET-1 in con ...

Background Giant-cell arteritis (GCA) is an inflammatory disease of large/medium-sized arteries, frequently involving the temporal arteries (TA). Inflammation-induced vascular remodelling leads to ...

Swiss pharma company Idorsia announced that its novel dual endothelin receptor antagonist (ERA), Tryvio (aprocitentan), has ...

高血压，这个“沉默的杀手”总是悄然而至，影响 平台声明：该文观点仅代表作者本人，搜狐号系信息发布平台，搜狐仅提供信息存储空间服务。

Focal Segmental Glomerulosclerosis (FSGS) is a rare kidney disorder characterized by scarring (sclerosis) in the glomeruli, leading to proteinuria, progressive kidney damage, and potential kidney ...

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Opsumit tablets, 10 mg, of ...

Deepak L. Bhatt, MD, MPH, MBA, of Mount Sinai Fuster Heart Hospital, spoke at the recent ASPC 2025 Congress on CVD Prevention ...

诺华创新产品诺锐达®（盐酸阿曲生坦片）获得国家药品监督管理局批准，用于降低有疾病快速进展风险的原发性免疫球蛋白A肾病（ IGA肾病 ）成人患者的蛋白尿。一般来说，这类患者的尿蛋白肌酐比值（UPCR）≥ ...

Vadodara: Alembic Pharmaceuticals Limited today announced that the company has received final approval from the US Food & ...